rofecoxib has been researched along with Peptic Ulcer in 43 studies
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicentre, randomised, double blind, 12 week study, patients with rheumatoid arthritis were allocated to rofecoxib 50 mg once daily (n=219), naproxen 500 mg twice daily (n=220), or placebo (n=221)." | 9.10 | Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. ( Evans, J; Hawkey, CJ; Laine, L; Quan, H; Shingo, S; Simon, T, 2003) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 9.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| "In this multicentre, randomised, double blind, 12 week study, patients with rheumatoid arthritis were allocated to rofecoxib 50 mg once daily (n=219), naproxen 500 mg twice daily (n=220), or placebo (n=221)." | 5.10 | Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. ( Evans, J; Hawkey, CJ; Laine, L; Quan, H; Shingo, S; Simon, T, 2003) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 5.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| " Dosing should be [figure: see text] cautious in old patients, however, because of the ability of NSAIDs and coxibs to cause fluid retention, heart failure, and hypertension." | 2.41 | Gastrointestinal safety of COX-2 specific inhibitors. ( Hawkey, CJ; Jones, JI, 2001) |
| "Celecoxib and rofecoxib have been used in Norway since 2000." | 2.41 | [A critical evaluation of side effect data on COX-2 inhibitors]. ( Pomp, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 39 (90.70) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almansa, C | 1 |
| Alfón, J | 1 |
| de Arriba, AF | 1 |
| Cavalcanti, FL | 1 |
| Escamilla, I | 1 |
| Gómez, LA | 1 |
| Miralles, A | 1 |
| Soliva, R | 1 |
| Bartrolí, J | 1 |
| Carceller, E | 1 |
| Merlos, M | 1 |
| García-Rafanell, J | 1 |
| Schneeweiss, S | 1 |
| Glynn, RJ | 1 |
| Avorn, J | 1 |
| Mamdani, M | 1 |
| Mogun, H | 1 |
| Solomon, DH | 1 |
| Stover, RR | 1 |
| Wiens, BL | 1 |
| Heyse, JF | 1 |
| Lehmann, FS | 1 |
| Gyr, N | 1 |
| Hawkey, CJ | 5 |
| Laine, L | 2 |
| Simon, T | 1 |
| Quan, H | 3 |
| Shingo, S | 1 |
| Evans, J | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Sturkenboom, MC | 1 |
| Burke, TA | 1 |
| Dieleman, JP | 1 |
| Tangelder, MJ | 1 |
| Lee, F | 1 |
| Goldstein, JL | 1 |
| Lamarque, D | 1 |
| Chang, SY | 1 |
| Howden, CW | 1 |
| Hollenz, M | 1 |
| Labenz, J | 1 |
| Dai, C | 1 |
| Stafford, RS | 1 |
| Alexander, GC | 1 |
| McCarthy, DM | 1 |
| Klasser, GD | 1 |
| Epstein, J | 1 |
| Lanas, A | 1 |
| Baron, JA | 1 |
| Sandler, RS | 1 |
| Horgan, K | 1 |
| Bolognese, J | 1 |
| Oxenius, B | 1 |
| Watson, D | 1 |
| Cook, TJ | 1 |
| Schoen, R | 1 |
| Burke, C | 1 |
| Loftus, S | 1 |
| Niv, Y | 1 |
| Ridell, R | 1 |
| Morton, D | 1 |
| Bresalier, R | 1 |
| Takeuchi, K | 1 |
| Tanaka, A | 1 |
| Kato, S | 1 |
| Aihara, E | 1 |
| Amagase, K | 1 |
| Schachna, L | 1 |
| Ryan, PF | 1 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Watson, DJ | 1 |
| Harper, SE | 2 |
| Zhao, PL | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 2 |
| Dionne, R | 1 |
| Blondon, H | 1 |
| Goldkind, L | 1 |
| Bombardier, C | 1 |
| Reicin, A | 1 |
| Shapiro, D | 1 |
| Burgos-Vargas, R | 1 |
| Davis, B | 1 |
| Day, R | 1 |
| Ferraz, MB | 1 |
| Hochberg, MC | 1 |
| Kvien, TK | 1 |
| Schnitzer, TJ | 1 |
| Jackson, L | 1 |
| Mortensen, E | 1 |
| Lines, CR | 1 |
| Brzozowski, T | 1 |
| Konturek, PC | 1 |
| Konturek, SJ | 1 |
| Pajdo, R | 1 |
| Schuppan, D | 1 |
| Drozdowicz, D | 1 |
| Ptak, A | 1 |
| Pawlik, M | 1 |
| Nakamura, T | 1 |
| Hahn, EG | 1 |
| Simon, B | 1 |
| Kellner, H | 1 |
| Lems, WF | 1 |
| van de Laar, MA | 1 |
| Bijlsma, JW | 1 |
| Patrono, C | 1 |
| Patrignani, P | 1 |
| García Rodríguez, LA | 1 |
| Nguyen, A | 1 |
| Chaiton, A | 1 |
| Nakamura, H | 1 |
| Jones, JI | 1 |
| Brinker, AD | 1 |
| Bonnel, RA | 1 |
| Feight, AG | 1 |
| Nourjah, P | 1 |
| Pomp, E | 1 |
| Miyake, K | 1 |
| Sakamoto, C | 1 |
| Shaughnessy, AF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386] | Phase 3 | 2,586 participants (Actual) | Interventional | 1999-12-23 | Completed | ||
| Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model[NCT00026819] | Phase 2 | 150 participants | Interventional | 2001-11-30 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001] | Phase 4 | 60 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for rofecoxib and Peptic Ulcer
| Article | Year |
|---|---|
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Gastroint | 2004 |
Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Cyclooxygenase Inhibitors; Diclofenac; Gas | 2002 |
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials | 2005 |
COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 1999 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2001 |
[Safety of specific cyclo-oxygenase 2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Humans; Inci | 2001 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova | 2001 |
Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pep | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
Arthritis. Should you be taking a COX-2 inhibitor?
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 1; Cycloo | 2001 |
Gastrointestinal safety of COX-2 specific inhibitors.
Topics: Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygena | 2001 |
[A critical evaluation of side effect data on COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
[Prophylaxis against non-steroidal anti-inflammatory drug-associated ulcers and erosions].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2002 |
5 trials available for rofecoxib and Peptic Ulcer
| Article | Year |
|---|---|
Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cycl | 2003 |
Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
Topics: Adenomatous Polyps; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Europe; | 2007 |
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
[The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Endoscopy, Gastrointestinal; | 2001 |
21 other studies available for rofecoxib and Peptic Ulcer
| Article | Year |
|---|---|
Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Binding Sites | 2003 |
NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cyclooxy | 2009 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cycloox | 2002 |
Testing for interaction in studies of noninferiority.
Topics: Bias; Computer Simulation; Confidence Intervals; Data Interpretation, Statistical; Humans; Lactones; | 2003 |
Underutilization of preventive strategies in patients receiving NSAIDs.
Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cohort | 2003 |
[Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Clinical Trials a | 2004 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
[Gastrointestinal complications under NSAID treatment in the doctor's office].
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Clinical Trials as Topic; Dicl | 2004 |
National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
Topics: Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Attitude of Health Personnel | 2005 |
Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa.
Topics: Animals; Benzamides; Benzoates; Gastric Mucosa; Indomethacin; Intestinal Mucosa; Lactones; Peptic Ul | 2007 |
New versus old drugs for arthritis.
Topics: Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Huma | 1999 |
COX-2 inhibitors. Magic bullets or merely mortal?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
COX-2 inhibitors: better than ibuprofen for dental pain?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 1999 |
Refecoxib versus placebo ulcer rates.
Topics: Cyclooxygenase Inhibitors; Humans; Intestinal Mucosa; Lactones; Peptic Ulcer; Placebos; Randomized C | 2000 |
Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor.
Topics: Animals; Antibodies; Blotting, Western; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit | 2000 |
[Prof. Bernd Simon on nonsteroidal anti-inflammatory drugs. Gastrointestinal complications are unpredictable].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Humans; Lactones; Peptic Ulcer; | 2001 |
[Therapy of arthrosis. Life threatening gastrointestinal events can be reduced].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 2001 |
[Results of the VIGOR study. Rofecoxib halves the complication rate].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relationship, Dr | 2001 |
[Selective COX-2 inhibitor. Stomach protection--but not always].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycl | 2001 |
Celecoxib and rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Hemo | 2001 |
Right ballpark, wrong base: assessing safety of NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pep | 2002 |